ROXALL Group

Spanish Society of Allergology and Clinical Immunology (SEAIC) Congress is happening in Bilbao, Spain! #ROXALL, welcomes all participants, organizers, speakers and moderators of the #SEAIC International Symposium “Life-threatening Allergic Diseases”. We are excited to kick off these exciting days, where very relevant topics will be addressed and discussed. Our backpack is packed with excitement! We are delighted to meet you at booths 1-2-6-7. https://lnkd.in/d7x8Cf-R Improving Your Life with ROXALL! #roxall #roxallgroup #allergy #alergia #seaic #seaic2024

Escuela de VENENOX 3rd edition from ROXALL is hapenning next week. Countdown has started! #roxall #roxallgroup #allergy #venomimmunotherapy #eaaci

2nd Edition of the #EscuelaÁcarox by ROXALL Medicina España ! On October 4th - 5th, 2024 there were two intense days of learning and debate on a crucial topic #mitesallergy. ROXALL addressed the latest developments, current challenges and new perspectives. A special thank you to all attendees for active participation and enthusiasm. To the speakers whose experience and knowledge allowed us to deepen, creating a space for dialogue. Progress in this area is promising, and we at #ROXALL are convinced that, with everyone's collaboration, we will continue to find better solutions. We continue, moving forward together towards the future. Improving Your Life with ROXALL! #roxall #roxallgroup #allergy #mitesallergy #allergenimmunotherapy #allergology #allergytreatment

ROXALL Group is one of the leading manufacturers for venom immunotherapy (VIT) products. During EAACI Allergy School which was organized on 19th to 21th September, 2024 in Bilbao, Spain the session "Straight to the VIT: Characterization of Hymenoptera venoms and selection of optimal VIT based on patient’s diagnosis" was presented by Gabriela Prêtre PhD from ROXALL and Joana Cosme MD. ROXALL contributes into the research and development of vaccines against Hymenoptera venom allergy, one of the most common causes of severe allergic reactions. It helps allergy patients to have a safe life. Improving Your Life with ROXALL! #roxall #roxallgroup #venomimmunotherapy #eaaci #eaaciallergyschool

At #ROXALL, we are excited to launch the 2nd Edition of the Acarox School. This interactive, hands-on course will provide the most innovative tools to address mite-related pathologies.  This course will introduce:  - Up-to-date knowledge that you can apply directly to your clinical practice.  - Personalized strategies to improve your patients' quality of life and reduce the impact of complications such as asthma. This opportunity can help for the allergologist to grow professionally and improve the lives of the patients! Improving your life with ROXALL! #roxall #roxallgroup #allergy #mitesallergy #allergenspecificimmunotherapy

🔎 We're proud to have participated in the EAACI Allergy School 2024 with Gabriela Pretre and Joana Cosme as Opinion Leaders in our #StraightToTheVIT Symposium. Move forward with us into the #FUTURE at Venom Immunotherapy 🐝

🎓 Allergy School 2024: Wrapping Up an Incredible Journey in Bilbao! As we head into the final stretch of #AllergySchool2024 this evening, we’ve already had a day filled with cutting-edge knowledge: 🔬 Lecture Session V: Insects in a Changing World with Drs. K. Spriggs, A. Vega Castro, and C. Breynaert explore the impact of our environment on insect populations and allergy triggers. 💡 Session VI: Exploring the Future of Insect Venom Hypersensitivity with Drs. B.M. Bilò, H. Oude Elberink, T. Alfaya Arias, and T. Rama, tackling the latest advances in diagnosis and treatment. Later today, we’ll close with Oral Presentation Session 2 and the Closing Ceremony, marking the end of this incredible meeting. EAACI remains committed to advancing allergy research and improving patient health worldwide. Thank you for being so dedicated, and we’ll see you at FAAM-EUROBAT 2024! https://ow.ly/cJ8u50Tsho7 #AllergySchool2024 #EAACI #InsectVenomAllergy #Bilbao #AllergyExperts #MedicalResearch #FAAMEUROBAT2024

🕒 Today, we are waiting for you at our Symposium at 3:00 p.m. 👩🔬👩⚕️ Gabriela Pretre, PhD and Joana Cosme, a perfect tandem, will talk about the importance of the characterization of #HymenopteraVenoms as well as the selection of the #therapy based in the #diagnosis of #allergicpatients 🐝 Move forward with us into the FUTURE #ROXALL

Insect sting allergies – wasp venom hypersensitivity Insect venom allergy is one of the common and most dangerous summertime allergies. Insect bites and stings lead to different symptoms in susceptible individuals, from local pain and redness to severe systemic reactions up to life-threatening anaphylaxis. A common wasp is another widespread Hymenoptera insect, which is native for the Northern Hemisphere, but can also be found in Australia, New Zealand, and South Africa. Unlike honeybees, common wasps can sting their victims multiple times during their lifetime.   Currently, 6 wasp allergens are characterized on the molecular level. Ves v 1 and Ves v 5 are the most common triggers of wasp venom allergy. Ves v 1 belongs to phospholipase A1 enzymes with the absence of cross reactivity with Api m 1, a phospholipase A2, from honeybee venom. Ves v 1 is responsible for developing allergic symptoms in over 60% of sensitized individuals. Ves v 5 triggers allergy symptoms even more efficiently, up to 98 sensitized individuals experience signs of venom allergy in response to Ves v 5.   The European hornet is found mostly in Europe and Asia. Stings of European hornet are quite occasional, yet dangerous as they can induce severe and even fatal reactions such as anaphylaxis. Hornets build their colonies on ground or in shelters and sting their victims for self-defence. Three hornet venom allergens have been characterized: Vesp c 1, Vesp c 2, and Vesp c 5, the most allergenic component of hornet venom.   As complete avoidance of contact with stinging insects is almost impossible and could not be fully controlled, the only efficient way to get rid of the cause, not the symptoms, is allergen-specific immunotherapy (AIT, or venom immunotherapy (VIT) in case of allergy to insect venoms). ROXALL pays a particular attention to the research and development of vaccines against Hymenoptera venom allergy, one of the most common causes of severe allergic reactions. In our developing and manufacturing process, we implement the latest scientific findings that comes from the deep understanding of insect biology and biochemistry of venoms combined with state-of-the-art technologies to ensure the highest quality and safety of our vaccines. Improving Your Life with ROXALL! #roxall #roxallgroup #allergy #allergenimmunotherapy #venomallergy #VIT

Insect sting allergies – bee venom hypersensitivity   Insect venom allergy is one of the common and most dangerous summertime allergies. Insect bites and stings lead to different symptoms in susceptible individuals, from local pain and redness to severe systemic reactions up to life-threatening anaphylaxis.   Honeybee can sting its victims only once leaving the sting with a venom sac in the skin of an animal of a human that disturbed an insect (which is eventually lethal for a honeybee itself). Thus, a sting should be removed very carefully to avoid sac squeezing and letting even more venom enter the skin. As honeybees are easily found in nature and cultivated worldwide for honey and pollination of cultured plants, contact with these insects is quite common during summer. Beekeepers are of greater risk of developing allergy and anaphylaxis due to bee stings.   Honeybee venom contains different proteins including enzymes, biogenic amines, phospholipids. 12 allergenic proteins from honeybee venom have been characterized. Api m 1, Api m 2, Api m 3, Api m 5, and Api m 10 are considered as major allergens of honeybee venom, but their prevalence can vary considerably depending on geographic areas, patient population.   Among them, sensitization to Api m 1 and Api m 10 are the most prevalent. Some allergens, such as Api m 4 (mellitin) can act as toxins. From the molecular point of view, Api m 1 is an enzyme phospholipase A2 that plays roles in numerous cellular processes such as phospholipid metabolism, signal transduction, and immune and inflammatory response regulation.   As complete avoidance of contact with stinging insects is almost impossible and could not be fully controlled, the only efficient way to get rid of the cause, not the symptoms, is allergen-specific immunotherapy (AIT, or venom immunotherapy (VIT) in case of allergy to insect venoms).   ROXALL pays a particular attention to the research and development of vaccines against Hymenoptera venom allergy, one of the most common causes of severe allergic reactions.   In our developing and manufacturing process, we implement the latest scientific findings that comes from the deep understanding of insect biology and biochemistry of venoms combined with state-of-the-art technologies to ensure the highest quality and safety of our vaccines.   Improving Your Life with ROXALL! #roxall #roxallgroup #allergy #beevenomallergy #venomimmunotherapy